Legend joins the billion-dollar club
With a $3.2bn valuation ahead of its Nasdaq float – and a market cap that is now 50% higher – Legend Biotech enters the IPO record books.
Ash 2019 – Johnson & Johnson overshadows Bluebird’s registrational reveal
This year’s Ash features numerous duelling anti-BCMA therapies in multiple myeloma, and the first clinical data for JNJ-4528 impress.
Ash 2019 preview – the first winner and losers emerge
Celgene’s registrational Transcend NHL-001 study will be a big story at Ash, but the early focus falls on what has not been presented.
Autolus slams on the brakes in its Car
Blaming manufacturing delays and competitive pressure, Autolus asks investors to reset expectations.
Ash 2018 – Legend’s mystery CAR raises more questions
Nanjing Legend reveals continuing strong responses with its anti-BCMA CAR-T therapy in multiple myeloma, but relapses, a death and missing patients cloud the results.
Ash 2018 preview – blood cancers offer biotech a chance at redemption
The Ash meeting starts on December 1. Here are some haematological cancer presentations that investors will be focusing on, as biotech risks ending 2018 in poor shape.
The rollercoaster ride continues for China’s cell therapy sector
Companies like Nanjing Legend and Cellular Biomedicine Group continue to attract major financial endorsement from Western big pharma, but the threat of scandal is…
Remission might not be the only factor in how the US pays for CAR-T
To determine whether Medicare covers CAR-T it might soon be important to find out how patients feel.